drugset / Trial / NCT03336450

Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Pediatric Patients With Status Epilepticus (Convulsive) in the Community Setting

NCT03336450

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if the investigational treatment, MHOS/SHP615, is safe and effective in children with status epilepticus (SE) (convulsive) in the community setting. This study is open-label extension for patients who completed the SHP615-301 study and who tolerated and responded to MHOS/SHP615 treatment in the hospital setting.

Timeline

Start
2018-04-23
Primary completion
2020-10-13
Completion
2020-10-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Midazolam Small molecule 2.5 mg Other
Subject Midazolam Small molecule 5 mg Other
Subject Midazolam Small molecule 7.5 mg Other
Subject Midazolam Small molecule 10 mg Other